EPO, erythropoietin, 2056

N. diseases: 646; N. variants: 11
Disease: Deep Vein Thrombosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0149871
Disease: Deep Vein Thrombosis
Deep Vein Thrombosis 		0.320 Biomarker disease BEFREE Results of the present meta-analysis suggest that the use of EPO may prevent death following TBI without causing adverse events, such as deep vein thrombosis. 30220640 2019
CUI: C0149871
Disease: Deep Vein Thrombosis
Deep Vein Thrombosis 		0.320 Biomarker disease BEFREE CONCLUSIONS The authors suggested that EPO is beneficial for patients with TBI in terms of reducing mortality and shortening hospitalization time without increasing the risk of DVT. 27367243 2017
CUI: C0149871
Disease: Deep Vein Thrombosis
Deep Vein Thrombosis 		0.320 Biomarker disease CTD_human Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin. 17547733 2007
CUI: C0149871
Disease: Deep Vein Thrombosis
Deep Vein Thrombosis 		0.320 Biomarker disease CTD_human Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha. 12670338 2003